Page 152 - Haematologica May 2022

A. Dodero et al.
statistically different among these three subgroups. In addition, we have to consider that the prognosis of high- grade B-cell lymphomas (HGBCL) with overexpression of MYC or BCL2 proteins seems poor as compared to DH/TH, not DEL.27 This finding suggests that more than 50% of DEL-DH/TH could be cured with an intensive reg-
imen but that in case of relapse they have a trend for poor overall survival. Likely, the recent Food and Drug Administration and European Medicines Agency approval of new therapies such as CAR-T cells will have an impact on the OS of relapsed DEL-DH/TH HGBCL.28,29
A total of 27 patients with limited-stage disease (stage I,
AB
CD
EF
Figure 2. Kaplan-Meier estimates of progression-free survival and overall survival according to TP53 mutation and central nervous prophylaxis. Progression-free survival (A, C and E) and overall survival (B, D and F) according to TP53 mutational status (A and B) and central nervous system prophylaxis (none, intrathecal, intra- venous methotrexate) including (C and-D) and excluding (E and F) high-grade B-cell lymphomas (double-hit/triple-hit [DH/TH]).
1160
haematologica | 2022; 107(5)